Unaudited Financial Results (Standalone & Consolidated) for the quarter & half year ended on 30th September, 2025 approved by the Board of Directors of the Company at their meeting held ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors approved unaudited Q2 and half-year FY26 results (standalone and consolidated) at their meeting on November 5, 2025. Auditor M/s R.K. Doshi & Co. LLP issued unmodified limited review reports. A notable event: subsidiary Dinesh Remedies Limited was fully disposed of effective September 3, 2025 and ceased to be a subsidiary from that date, with its results included only up to the cessation date. Standalone H1 FY26 Profit Before Tax was Rs 695.44 lakhs versus Rs 893.61 lakhs in H1 FY25. Consolidated H1 FY26 PBT was Rs 741.25 lakhs versus Rs 854.07 lakhs in the prior year period. Operating cash flow improved meaningfully on both bases — standalone Rs 334.31 lakhs (vs Rs 153.90 lakhs) and consolidated Rs 414.41 lakhs (vs Rs 209.19 lakhs).
Profit before tax declined roughly 20-22% year-on-year on a like-for-like comparison, which may weigh on near-term sentiment. However, the sharp improvement in operating cash flow and the simplification of the group structure following the Dinesh Remedies divestment are positives for the consolidated profile.